A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.

The approach harnesses the power of bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular "bottlenecks" that have limited the natural production of this drug for over 50 years.

Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s.

A topical cream activated the skin’s immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published in the Journal of Clinical Investigation. Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream works by blocking LSD1, an enzyme that suppresses immune‑activating pathways in the skin.

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.

A new discovery from researchers at The University of Texas at Austin and The University of Texas MD Anderson Cancer Center helps explain why some chemotherapy drugs not only eliminate cancer cells directly, they - at least in some patients - actually trigger the innate immune system to attack cancer cells.

The researchers made this discovery while testing a potential chemotherapy agent referred to as Compound 1 - which causes a build-up of toxic molecules called reactive oxygen species - on preclinical models.

A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.

Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.

A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, helping them lead much healthier and happier lives, the findings of a UCL (University College London) and Great Ormond Street Hospital-led international clinical trial show.

In a new paper published in The New England Journal of Medicine, the researchers found that children with Dravet syndrome had up to 91 per cent fewer seizures while being regularly administered a new medication called zorevunersen.